IRVINE, Calif., July 28 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. announced today that the Company has been named as a founding member of a new NASDAQ Health Care Index.
The NASDAQ Health Care Index is a market value weighted index that contains NASDAQ-listed companies classified, according to the FTSE Global Classification System, as “Health”, “Pharmaceutical”, or “Biotechnology”. The NASDAQ Health Care Index will join other world-class indexes, such as the NASDAQ-100 Index and the NASDAQ Biotechnology Index.
“We are pleased to be included in this new index, which underscores the progress we have made in building a solid pharmaceutical business from the ground up in just under three years,” stated Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President. “This also provides greater recognition of Spectrum’s efforts in the health care industry and our commitment to acquiring and developing prescription drugs for the treatment of cancer and other unmet medical needs.”
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a specialty pharmaceutical company engaged in the business of acquiring, developing and commercializing prescription drug products for the treatment of cancer and other unmet medical needs. By leveraging its operational flexibility and regulatory proficiency, and using the extensive research and development capabilities of its strategic alliance partners, Spectrum has built a diversified portfolio of proprietary and generic drug products in various stages of development and regulatory approval. For more information, please visit our website at http://www.spectrumpharm.com .
Forward-looking statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, the Company’s operational flexibility and regulatory proficiency, the extensive research and development capabilities of the Company’s strategic alliance partners, the new index’s ability to provide greater recognition for Spectrum, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company’s reports filed with the Securities and Exchange Commission.
Contact: Laurie Little Sr. Director, Investor Relations (949) 743-9216
Spectrum Pharmaceuticals, Inc.
CONTACT: Laurie Little, Sr. Director, Investor Relations, SpectrumPharmaceuticals, Inc., +1-949-743-9216
Web site: http://www.spectrumpharm.com/